Sage Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:SAGE)

Analyst Price Target for SAGE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$78.00

▼ -14.64% Downside Potential

This price target is based on 18 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $78.00, with a high forecast of $135.00 and a low forecast of $28.00. The average price target represents a -14.64% upside from the last price of $91.38.

Buy

The current consensus among 18 contributing investment analysts is to buy stock in Sage Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
11 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

7/28/2019

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/26/2019

0 strong buy ratings
11 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/24/2020

0 strong buy ratings
13 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/23/2020

0 strong buy ratings
12 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

7/22/2020

0 strong buy ratings
11 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/20/2020

0 strong buy ratings
10 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

12/19/2020

0 strong buy ratings
10 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

1/18/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/4/2021	Guggenheim	Upgrade	Neutral ➝ Buy		N/A	i
1/4/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$83.00 ➝ $86.00	N/A	i
12/4/2020	William Blair	Reiterated Rating	Buy		Low	i
12/4/2020	Mizuho	Upgrade	Neutral ➝ Buy	$77.00 ➝ $81.00	Low	i
12/1/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target		$100.00 ➝ $93.00	Low	i
12/1/2020	Truist	Boost Price Target		$60.00 ➝ $70.00	Low	i
12/1/2020	Smith Barney Citigroup	Lower Price Target		$100.00 ➝ $93.00	Low	i
12/1/2020	Royal Bank of Canada	Lower Price Target		$86.00 ➝ $83.00	Low	i
12/1/2020	HC Wainwright	Lower Price Target	Neutral	$81.00 ➝ $74.00	Low	i Rating by D. Tsao at HC Wainwright
12/1/2020	Morgan Stanley	Lower Price Target	Equal Weight	$85.00 ➝ $83.00	Low	i
11/30/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		Low	i Rating by Dane Leone at Raymond James
11/19/2020	Oppenheimer	Boost Price Target		$65.00 ➝ $94.00	Medium	i
11/16/2020	Bank of America	Boost Price Target	Buy	$72.00 ➝ $95.00	High	i
11/16/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$87.00 ➝ $85.00	High	i
11/10/2020	Truist	Boost Price Target	Hold	$35.00 ➝ $60.00	Low	i
11/6/2020	Smith Barney Citigroup	Boost Price Target		$67.00 ➝ $100.00	Low	i
11/6/2020	Canaccord Genuity	Boost Price Target	Buy	$82.00 ➝ $135.00	Low	i
11/6/2020	Mizuho	Boost Price Target	Neutral	$53.00 ➝ $77.00	Medium	i
11/6/2020	BMO Capital Markets	Boost Price Target	Outperform	$79.00 ➝ $89.00	Medium	i
11/6/2020	HC Wainwright	Boost Price Target	Neutral	$76.00 ➝ $81.00	Medium	i Rating by D. Tsao at HC Wainwright
10/20/2020	Royal Bank of Canada	Boost Price Target	Outperform	$75.00 ➝ $84.00	Low	i Rating by Brian Abrahams at Royal Bank of Canada
10/16/2020	BMO Capital Markets	Boost Price Target	Positive ➝ Outperform	$65.00 ➝ $79.00	High	i
9/11/2020	Citigroup	Boost Price Target	Positive ➝ Buy	$54.00 ➝ $67.00	Low	i
9/11/2020	Wedbush	Upgrade	Neutral ➝ Outperform	$40.00 ➝ $65.00	Low	i Rating by L. Chico at Wedbush
8/24/2020	Morgan Stanley	Boost Price Target	Overweight	$85.00 ➝ $87.00	Medium	i
8/11/2020	Royal Bank of Canada	Reiterated Rating	Buy		Medium	i Rating by Brian Abrahams at Royal Bank of Canada
8/11/2020	Oppenheimer	Boost Price Target	Outperform	$50.00 ➝ $65.00	High	i
8/10/2020	Raymond James	Upgrade	Market Perform ➝ Outperform	$70.00	Low	i
8/10/2020	Mizuho	Reiterated Rating	Hold	$44.00	High	i
5/26/2020	Royal Bank of Canada	Boost Price Target	Outperform	$72.00 ➝ $75.00	Low	i Rating by Brian Abrahams at Royal Bank of Canada
5/8/2020	SunTrust Banks	Lower Price Target	Hold	$37.00 ➝ $35.00	High	i
5/8/2020	Royal Bank of Canada	Boost Price Target	Outperform	$71.00 ➝ $72.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
5/8/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$36.00 ➝ $37.00	Medium	i Rating by L. Chico at Wedbush
5/8/2020	Mizuho	Boost Price Target	Neutral	$36.00 ➝ $44.00	Medium	i Rating by Vamil Divan at Mizuho
4/28/2020	Royal Bank of Canada	Boost Price Target	Outperform	$68.00 ➝ $71.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
4/19/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
4/9/2020	BMO Capital Markets	Lower Price Target	Outperform	$86.00 ➝ $65.00	Medium	i
4/9/2020	SunTrust Banks	Lower Price Target	Hold	$40.00 ➝ $37.00	Medium	i
4/8/2020	Canaccord Genuity	Lower Price Target	Buy	$96.00 ➝ $80.00	Low	i
4/8/2020	Royal Bank of Canada	Boost Price Target	Outperform	$60.00 ➝ $68.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
4/8/2020	Wedbush	Lower Price Target	Outperform	$56.00 ➝ $36.00	High	i
4/8/2020	Oppenheimer	Lower Price Target	Outperform	$60.00 ➝ $50.00	High	i
4/8/2020	Citigroup	Boost Price Target	Buy	$48.00 ➝ $54.00	High	i Rating by Neena Bitritto-Garg at Citigroup Inc.
4/8/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
4/8/2020	Mizuho	Lower Price Target	Neutral	$58.00 ➝ $36.00	High	i Rating by Vamil Divan at Mizuho
3/26/2020	SunTrust Banks	Lower Price Target	Hold	$50.00 ➝ $40.00	Medium	i
3/22/2020	HC Wainwright	Reiterated Rating	Hold	$78.00	Low	i Rating by Douglas Tsao at HC Wainwright
3/20/2020	LADENBURG THALM/SH SH	Reiterated Rating	Hold	$28.00	High	i
3/19/2020	Oppenheimer	Lower Price Target		$97.00 ➝ $60.00	Low	i
3/19/2020	SVB Leerink	Boost Price Target	Market Perform	$45.00 ➝ $63.00	Low	i Rating by Marc Goodman at SVB Leerink LLC
3/19/2020	Guggenheim	Lower Price Target	Buy	$85.00 ➝ $65.00	Low	i
3/19/2020	Citigroup	Lower Price Target	Buy	$71.00 ➝ $48.00	Low	i Rating by Neena Bitritto-Garg at Citigroup Inc.
3/18/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$73.00 ➝ $60.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
3/11/2020	Mizuho	Reiterated Rating	Hold	$58.00	High	i Rating by Vamil Divan at Mizuho
3/5/2020	Citigroup	Initiated Coverage	Buy	$71.00	High	i
3/3/2020	Morgan Stanley	Lower Price Target	Overweight	$125.00 ➝ $117.00	Medium	i Rating by Matthew Harrison at Morgan Stanley
2/28/2020	SunTrust Banks	Lower Price Target	Hold	$60.00 ➝ $50.00	High	i
2/28/2020	LADENBURG THALM/SH SH	Reiterated Rating	Hold	$52.00	High	i
2/28/2020	HC Wainwright	Lower Price Target	Neutral	$87.00 ➝ $78.00	High	i Rating by Douglas Tsao at HC Wainwright
2/28/2020	Mizuho	Lower Price Target	Neutral	$69.00 ➝ $58.00	High	i Rating by Vamil Divan at Mizuho
2/27/2020	Cowen	Reiterated Rating	Buy	$96.00	High	i
2/27/2020	Mizuho	Reiterated Rating	Hold	$69.00	High	i Rating by Vamil Divan at Mizuho
2/5/2020	Mizuho	Initiated Coverage	Neutral	$69.00	Low	i
1/7/2020	Bank of America	Boost Price Target		$85.00 ➝ $98.00	Medium	i
12/6/2019	Oppenheimer	Lower Price Target		$190.00 ➝ $100.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/6/2019	JPMorgan Chase & Co.	Lower Price Target	Overweight	$200.00 ➝ $105.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
12/6/2019	LADENBURG THALM/SH SH	Downgrade	Buy ➝ Neutral		Low	i
12/6/2019	Royal Bank of Canada	Lower Price Target	Outperform	$190.00 ➝ $100.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
12/6/2019	Morgan Stanley	Lower Price Target	Overweight	$217.00 ➝ $125.00	High	i
12/6/2019	BMO Capital Markets	Reiterated Rating	Outperform	$92.00	High	i
12/6/2019	SVB Leerink	Upgrade	Underperform ➝ Market Perform		High	i Rating by M. Goodman at SVB Leerink LLC
12/6/2019	HC Wainwright	Lower Price Target	Neutral	$160.00 ➝ $87.00	High	i Rating by D. Tsao at HC Wainwright
12/5/2019	The Goldman Sachs Group	Lower Price Target		$227.00 ➝ $263.00	High	i
12/5/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$206.00 ➝ $125.00	High	i
12/5/2019	Guggenheim	Lower Price Target	Buy	$200.00 ➝ $110.00	High	i
12/5/2019	Cowen	Reiterated Rating	Buy	$96.00	High	i
12/5/2019	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$73.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
12/5/2019	Wedbush	Lower Price Target	Outperform	$203.00 ➝ $90.00	High	i
12/5/2019	SunTrust Banks	Downgrade	Buy ➝ Hold	$210.00 ➝ $70.00	High	i
11/25/2019	Royal Bank of Canada	Reiterated Rating	Buy	$235.00	Low	i Rating by Brian Abrahams at Royal Bank of Canada
11/24/2019	Morgan Stanley	Reiterated Rating	Buy	$217.00	Medium	i
11/20/2019	Stifel Nicolaus	Reiterated Rating	Buy		Low	i Rating by Paul Matteis at Stifel Nicolaus
10/30/2019	HC Wainwright	Initiated Coverage	Neutral	$160.00	Low	i Rating by D. Tsao at HC Wainwright
8/7/2019	Oppenheimer	Lower Price Target	Outperform	$200.00 ➝ $190.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/25/2019	Oppenheimer	Boost Price Target		$170.00 ➝ $200.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/24/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
7/24/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Tim Lugo at William Blair
5/22/2019	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$207.00	Low	i Rating by L. Chico at Wedbush
5/5/2019	Oppenheimer	Set Price Target	Buy	$170.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/2/2019	LADENBURG THALM/SH SH	Set Price Target	Buy	$220.00	Low	i Rating by Michael Higgins at LADENBURG THALM/SH SH
4/26/2019	Raymond James	Reiterated Rating	Market Perform		Medium	i
4/25/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$195.00	Low	i
4/8/2019	Canaccord Genuity	Set Price Target	Buy	$220.00	Low	i Rating by Sumant Kulkarni at Canaccord Genuity
2/22/2019	Guggenheim	Initiated Coverage	Buy	$205.00	High	i
12/19/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$230.00 ➝ $213.00	High	i
12/14/2018	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform		Medium	i
12/11/2018	LADENBURG THALM/SH SH	Set Price Target	Buy	$210.00	High	i Rating by Michael Higgins at LADENBURG THALM/SH SH
11/20/2018	Oppenheimer	Set Price Target	Buy	$170.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/12/2018	SVB Leerink	Initiated Coverage	Underperform	$80.00	High	i Rating by M. Goodman at SVB Leerink LLC
11/6/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$205.00	Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/5/2018	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$259.00 ➝ $261.00	Medium	i
11/4/2018	Oppenheimer	Set Price Target	Buy	$170.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/1/2018	Canaccord Genuity	Set Price Target	Buy	$220.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
11/1/2018	Cowen	Reiterated Rating	Buy	$207.00	High	i
10/31/2018	LADENBURG THALM/SH SH	Set Price Target	Buy	$235.00	High	i Rating by Michael Higgins at LADENBURG THALM/SH SH
10/29/2018	Oppenheimer	Set Price Target	Buy	$170.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/17/2018	Oppenheimer	Initiated Coverage	Buy	$170.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/11/2018	Morgan Stanley	Boost Price Target	Overweight	$228.00 ➝ $230.00	High	i
10/10/2018	Oppenheimer	Initiated Coverage	Buy	$170.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/8/2018	Canaccord Genuity	Set Price Target	Buy	$220.00	Low	i Rating by Sumant Kulkarni at Canaccord Genuity
8/7/2018	Stifel Nicolaus	Boost Price Target	Buy	$198.00 ➝ $239.00	Medium	i
8/6/2018	Piper Jaffray Companies	Initiated Coverage	Overweight	$206.00	Medium	i
7/13/2018	Morgan Stanley	Boost Price Target	Overweight	$225.00 ➝ $228.00	Low	i
6/14/2018	Cowen	Reiterated Rating	Buy	$207.00	Medium	i
6/12/2018	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$220.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
6/6/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy	$230.00	High	i
5/3/2018	Canaccord Genuity	Reiterated Rating	Buy	$210.00	Low	i Rating by Sumant Kulkarni at Canaccord Genuity
5/3/2018	Cowen	Reiterated Rating	Buy		Low	i
3/26/2018	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$210.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
3/20/2018	Cowen	Reiterated Rating	Buy	$202.00	Low	i
2/28/2018	SunTrust Banks	Boost Price Target	Buy	$203.00	Low	i Rating by Edward Nash at SunTrust Banks, Inc.
2/26/2018	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight	$225.00	Low	i
2/23/2018	Needham & Company LLC	Reiterated Rating	Buy	$193.00	Low	i Rating by Danielle Brill at Needham & Company LLC
1/10/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		High	i
12/11/2017	Cowen	Reiterated Rating	Buy		Low	i
12/8/2017	Stifel Nicolaus	Reiterated Rating	Buy	$198.00	Low	i Rating by Keith Gay at Stifel Nicolaus
12/8/2017	SunTrust Banks	Boost Price Target	Positive	$178.00	High	i Rating by Edward Nash at SunTrust Banks, Inc.
12/8/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$198.00	High	i
12/7/2017	Raymond James	Reiterated Rating	Buy	$206.00	High	i Rating by Laura Chico at Raymond James
12/7/2017	Canaccord Genuity	Set Price Target	Buy ➝ Buy	$140.00 ➝ $191.00	High	i Rating by John Newman at Canaccord Genuity
12/7/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $193.00	High	i Rating by Danielle Brill at Needham & Company LLC
12/7/2017	SVB Leerink	Boost Price Target		$123.00 ➝ $246.00	High	i
12/7/2017	BMO Capital Markets	Reiterated Rating	Outperform	$203.00	High	i
12/7/2017	Royal Bank of Canada	Boost Price Target	Outperform ➝ Sell	$137.00 ➝ $280.00	High	i
11/27/2017	Royal Bank of Canada	Lower Price Target	Outperform	$145.00 ➝ $137.00	Medium	i
11/17/2017	BMO Capital Markets	Reiterated Rating	Outperform	$85.67 ➝ $112.00	N/A	i
11/16/2017	Bank of America	Lower Price Target	Buy	$103.00 ➝ $101.00	N/A	i
11/15/2017	SunTrust Banks	Boost Price Target	Buy ➝ Positive	$116.00	N/A	i Rating by Edward Nash at SunTrust Banks, Inc.
11/10/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$86.00 ➝ $100.00	N/A	i Rating by Danielle Brill at Needham & Company LLC
11/10/2017	Chardan Capital	Upgrade	Neutral ➝ Buy	$60.00 ➝ $140.00	N/A	i Rating by G. Amusa at Chardan Capital
11/9/2017	Raymond James	Boost Price Target	Buy	$109.00	N/A	i
11/9/2017	Stifel Nicolaus	Boost Price Target	Buy	$91.00 ➝ $105.00	N/A	i Rating by Keith Gay at Stifel Nicolaus
11/9/2017	Royal Bank of Canada	Boost Price Target	Outperform	$145.00	N/A	i
11/9/2017	SVB Leerink	Boost Price Target	Outperform ➝ Positive	$85.00 ➝ $123.00	N/A	i
11/2/2017	Royal Bank of Canada	Boost Price Target		$117.00 ➝ $120.00	N/A	i
10/27/2017	BMO Capital Markets	Reiterated Rating	Buy	$80.00	N/A	i
10/19/2017	SunTrust Banks	Set Price Target	Buy	$82.00	N/A	i Rating by Edward Nash at SunTrust Banks, Inc.
10/18/2017	Royal Bank of Canada	Reiterated Rating	Buy	$117.00	N/A	i
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$87.00	N/A	i
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$117.00	Medium	i
9/14/2017	BMO Capital Markets	Boost Price Target	Outperform	$80.00 ➝ $84.00	High	i
9/13/2017	Chardan Capital	Reiterated Rating	Hold		High	i
9/13/2017	Needham & Company LLC	Lower Price Target	Buy ➝ Buy	$95.00 ➝ $86.00	High	i Rating by Danielle Brill at Needham & Company LLC
9/13/2017	Stifel Nicolaus	Reiterated Rating	Buy	$104.00 ➝ $91.00	High	i Rating by Keith Gay at Stifel Nicolaus
9/13/2017	SunTrust Banks	Reiterated Rating	Buy	$95.00 ➝ $82.00	High	i
9/12/2017	Canaccord Genuity	Lower Price Target	Buy	$110.00 ➝ $81.00	High	i Rating by John Newman at Canaccord Genuity
9/12/2017	JPMorgan Chase & Co.	Lower Price Target	Overweight	$99.00 ➝ $85.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
9/12/2017	Cowen	Lower Price Target	Outperform	$100.00 ➝ $90.00	Medium	i
8/31/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/9/2017	Stifel Nicolaus	Initiated Coverage	Buy	$104.00	Low	i
8/5/2017	Canaccord Genuity	Set Price Target	Buy	$110.00	Medium	i Rating by John Newman at Canaccord Genuity
8/4/2017	Cowen	Reiterated Rating	Buy	$100.00	Medium	i
8/4/2017	Needham & Company LLC	Set Price Target	Buy	$82.00 ➝ $95.00	High	i Rating by Danielle Brill at Needham & Company LLC
8/4/2017	HC Wainwright	Boost Price Target	Neutral	$86.00	High	i Rating by C. Werther at HC Wainwright
7/28/2017	BMO Capital Markets	Reiterated Rating	Buy	$82.00	Medium	i Rating by Gary Nachman at BMO Capital Markets
7/14/2017	Stifel Nicolaus	Reiterated Rating	Buy	$90.00	Medium	i
6/20/2017	SVB Leerink	Reiterated Rating	Outperform	$90.00 ➝ $97.00	High	i
6/13/2017	Needham & Company LLC	Reiterated Rating	Buy	$82.00	Medium	i
6/12/2017	Cowen	Initiated Coverage	Outperform	$95.00	Low	i
5/15/2017	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$82.00	Low	i
5/12/2017	Bank of America	Initiated Coverage	Buy ➝ Buy	$85.00	High	i
5/10/2017	Canaccord Genuity	Reiterated Rating	Buy	$110.00	Medium	i Rating by John Newman at Canaccord Genuity
4/12/2017	Canaccord Genuity	Set Price Target	Buy	$110.00	High	i Rating by John Newman at Canaccord Genuity
4/3/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$83.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
3/21/2017	Canaccord Genuity	Reiterated Rating	Buy	$110.00	High	i Rating by John Newman at Canaccord Genuity
3/6/2017	Canaccord Genuity	Set Price Target	Buy	$110.00	N/A	i Rating by John Newman at Canaccord Genuity
2/23/2017	Canaccord Genuity	Set Price Target	Buy	$110.00	N/A	i Rating by John Newman at Canaccord Genuity
2/22/2017	HC Wainwright	Downgrade	Buy ➝ Neutral	$56.00 ➝ $76.00	N/A	i Rating by C. Werther at HC Wainwright
2/22/2017	BMO Capital Markets	Boost Price Target	Outperform	$68.00 ➝ $82.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
2/14/2017	Chardan Capital	Upgrade	Sell ➝ Neutral	$60.00	N/A	i
2/13/2017	Cowen	Reiterated Rating	Buy	$95.00	N/A	i
2/13/2017	BMO Capital Markets	Set Price Target	Outperform ➝ Buy	$68.00	N/A	i
1/11/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
12/15/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$74.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
12/14/2016	Canaccord Genuity	Set Price Target	Buy	$110.00	N/A	i Rating by John Newman at Canaccord Genuity
12/14/2016	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$84.00	N/A	i
12/14/2016	UBS Group	Upgrade	Outperform ➝ Strong-Buy		N/A	i
12/6/2016	Canaccord Genuity	Reiterated Rating	Buy	$110.00	N/A	i Rating by john newman at Canaccord Genuity
11/14/2016	Stifel Nicolaus	Initiated Coverage	Buy	$90.00	N/A	i
11/3/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
10/4/2016	SVB Leerink	Reiterated Rating	Outperform	$68.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
9/19/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
9/13/2016	Raymond James	Initiated Coverage	Outperform	$75.00	N/A	i
9/6/2016	Canaccord Genuity	Set Price Target	Buy	$110.00	N/A	i Rating by john newman at Canaccord Genuity
8/12/2016	BMO Capital Markets	Reiterated Rating	Buy	$57.00	N/A	i Rating by Gary Nachman at BMO Capital Markets
7/15/2016	William Blair	Reiterated Rating	Outperform	$75.00	N/A	i Rating by Tim Lugo at William Blair
7/12/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$71.00	N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
7/12/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
7/12/2016	Chardan Capital	Reiterated Rating	Sell		N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
7/12/2016	BMO Capital Markets	Reiterated Rating	Buy		N/A	i Rating by Gary Nachman at BMO Capital Markets
7/12/2016	SVB Leerink	Reiterated Rating	Buy	$66.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
6/28/2016	BMO Capital Markets	Initiated Coverage	Outperform	$48.00	N/A	i
6/23/2016	HC Wainwright	Initiated Coverage	Buy	$56.00	N/A	i Rating by C. Werther at HC Wainwright
6/21/2016	SVB Leerink	Reiterated Rating	Outperform	$66.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
6/8/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity
6/8/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
6/8/2016	Chardan Capital	Reiterated Rating	Sell		N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital
5/27/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity
5/24/2016	Chardan Capital	Initiated Coverage	Sell	$18.00	N/A	i
5/16/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Paul Matteis at SVB Leerink LLC
5/14/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity
5/13/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
5/8/2016	Canaccord Genuity	Reiterated Rating	Buy	$110.00	N/A	i Rating by John Newman at Canaccord Genuity
4/8/2016	SVB Leerink	Reiterated Rating	Buy	$66.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
4/1/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$63.00	N/A	i Rating by Salveen Richter at The Goldman Sachs Group, Inc.
3/30/2016	The Goldman Sachs Group	Initiated Coverage	Neutral	$83.00	N/A	i
3/27/2016	William Blair	Reiterated Rating	Buy		N/A	i Rating by Tim Lugo at William Blair
3/24/2016	Canaccord Genuity	Reiterated Rating	Buy	$110.00	N/A	i Rating by John Newman at Canaccord Genuity
3/11/2016	Lake Street Capital	Initiated Coverage	Buy	$90.00	N/A	i Rating by C. Byrnes at Lake Street Capital
2/26/2016	SVB Leerink	Lower Price Target		$66.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
2/25/2016	William Blair	Lower Price Target	Outperform	$58.00	N/A	i Rating by Tim Lugo at William Blair
2/24/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity
2/24/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
2/24/2016	Cowen	Reiterated Rating	Buy	$108.00 ➝ $95.00	N/A	i
2/9/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by John Newman at Canaccord Genuity

(Data available from 1/19/2016 forward)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $91.38

$90.99

$97.67

50 Day Range

MA: $81.41

$68.57

$96.76

52 Week Range

Now: $91.38

$25.01

$98.39

Volume

18,289 shs

Average Volume

554,029 shs

Market Capitalization

$4.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Bank of America Co., BMO Capital Markets, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Guggenheim, HC Wainwright, LADENBURG THALM/SH SH, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Smith Barney Citigroup, SunTrust Banks, Inc., SVB Leerink LLC, Truist, Wedbush, and William Blair.

What is the current price target for Sage Therapeutics?

19 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $78.00, suggesting a possible downside of 14.6%. Canaccord Genuity has the highest price target set, predicting SAGE will reach $135.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $28.00 for Sage Therapeutics in the next year.

What is the current consensus analyst rating for Sage Therapeutics?

Sage Therapeutics currently has 8 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SAGE will outperform the market and that investors should add to their positions of Sage Therapeutics.

What other companies compete with Sage Therapeutics?

Other companies that are similar to Sage Therapeutics include Royalty Pharma, Alnylam Pharmaceuticals, Catalent, CureVac, Horizon Therapeutics Public, BioMarin Pharmaceutical, Elanco Animal Health, Grifols, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Mirati Therapeutics, Zai Lab, Bausch Health Companies, Jazz Pharmaceuticals and Ionis Pharmaceuticals.

How do I contact Sage Therapeutics' investor relations team?

Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-299-8380 and its investor relations email address is ir@sagerx.com. The official website for Sage Therapeutics is www.sagerx.com.

NASDAQ:SAGE - Sage Therapeutics Stock Price Target and Predictions

Analyst Price Target for SAGE

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

What is the current price target for Sage Therapeutics?

What is the current consensus analyst rating for Sage Therapeutics?

What other companies compete with Sage Therapeutics?

How do I contact Sage Therapeutics' investor relations team?